FindTrial
Sign In

Glufosfamide

DRUG9 trials

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC, Threshold Pharmaceuticals, Eleison Pharmaceuticals LLC.

Conditions

Brain and Central Nervous System TumorsCarcinoma, Small Cell LungLung CancerMetastatic Pancreatic AdenocarcinomaNeoplasmsOvarian CancerPancreatic CancerPancreatic Neoplasms

Phase 1

Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
CompletedNCT00102752
Threshold PharmaceuticalsNeoplasms, Pancreatic Neoplasms
Start: 2004-12-31End: 2007-07-31Target: 47Updated: 2009-04-30

Phase 2

Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme
CompletedNCT00014300
European Organisation for Research and Treatment of Cancer - EORTCBrain and Central Nervous System Tumors
Start: 2001-01-31Updated: 2012-09-24
Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer
CompletedNCT00005053
European Organisation for Research and Treatment of Cancer - EORTCPancreatic Cancer
Start: 1999-12-31Updated: 2012-09-24
Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer
CompletedNCT00005055
European Organisation for Research and Treatment of Cancer - EORTCLung Cancer
Start: 2000-01-31Updated: 2012-09-24
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
TerminatedNCT00435578
Threshold PharmaceuticalsCarcinoma, Small Cell Lung
Start: 2007-02-28End: 2007-11-30Target: 50Updated: 2009-04-30
Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma
CompletedNCT00441467
Eleison Pharmaceuticals LLC.Soft Tissue Sarcoma
Start: 2007-03-31End: 2008-10-31Updated: 2015-03-25
Safety and Efficacy Study of Glufosfamide in Ovarian Cancer
TerminatedNCT00442598
Eleison Pharmaceuticals LLC.Ovarian Cancer
Start: 2007-01-31End: 2008-04-30Updated: 2015-03-10

Phase 3

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
CompletedNCT00099294
Threshold PharmaceuticalsPancreatic Cancer
Start: 2004-09-30End: 2007-01-31Target: 300Updated: 2009-04-30
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
RecruitingNCT01954992
Eleison Pharmaceuticals LLC.Metastatic Pancreatic Adenocarcinoma
Start: 2014-04-30End: 2026-12-31Target: 480Updated: 2024-12-31